Yoga Intervention for Cancer Survivors
Impaired health related quality of life (HRQOL) including fatigue, problems with sleep and psychosocial well being (physical, emotional, and spiritual) have been noted in adult cancer survivors. Physical domain is one of the most common measured indicators of HRQOL. Despite the tremendous implications of having an impaired QOL, few studies have staged interventions aimed at improving HRQOL in a heterogeneous group of cancer survivors. There is little literature examining whether a yoga intervention is feasible in a heterogeneous group of cancer survivors.
The proposed research will utilize Vanderbilt Ingram Cancer Center (VICC), Nashville General Hospital (NGH) and REACH for Survivorship program for a pilot study. The investigators will see if a study using a broad range of diagnoses is feasible for a Yoga Intervention.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Yoga Intervention for Cancer Survivors|
- Number of Cancer Survivors interested and willing to participate in a 10 week yoga class at Vanderbilt Ingram Cancer Center (VICC) and at Nashville General Hospital [ Time Frame: 12 months ]The investigators will be opening up an hourly yoga class for 10 weeks to all cancer survivors at VICC and at Nashville General Hospital
- Levels of Fatigue using the SF-36 and Psychological Distress using BSI-18 [ Time Frame: 12 months ]Participants in the Yoga Study will be asked to complete the SF-36 and BSI-18 at three different time points in the study. Prior to start of a yoga class, at the end of the 10 week yoga class and 3 months after the completion of the yoga class.
|Study Start Date:||February 2010|
|Study Completion Date:||March 2012|
|Primary Completion Date:||March 2012 (Final data collection date for primary outcome measure)|
Group will enter a 10 week yoga class
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01228955
|United States, Tennessee|
|Vanderbilt University Medical Center|
|Nashville, Tennessee, United States, 37232|
|Principal Investigator:||Debra L Friedman, MD, MS||Vanderbilt University Medical Center|